18:06:11 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-09-22 Kvartalsrapport 2023-Q2
2023-06-09 Årsstämma 2023
2023-04-21 Bokslutskommuniké 2022
2022-09-22 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020


ListaMERK Equities
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.
2022-03-28 14:57:33
OSLO/LONDON, 28 March 2022: EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth:
EXTX), a clinical stage precision health company utilising Acoustic Cluster
Therapy (ACT®) across multiple therapeutic areas, announces that its Board of
Directors has today appointed Dr Per Walday as Chief Executive Officer (CEO).

A successful senior executive in the healthcare industry, Per has experience
from research to commercialization of therapeutics and medical devices globally,
including drug-device combination within the field of oncology. As CEO of PCI
Biotech (OSE: PCIB), Per built an effective organization that progressed the
platform technology into a pipeline of assets including in late stage clinical
programs through FDA and EMA regulatory paths. Prior to this, Per spent almost
two decades with Nycomed Imaging and GE Healthcare based in Norway where, as
Global Head Project Management, he was responsible for all development programs
of new pharmaceutical products. These included R&D efforts within the field of
ultrasound and microbubbles which paved the way for what would become years
later EXACT-Tx's Acoustic Cluster Therapy (ACT®). Per has a six months' notice